Core Viewpoint - XuanZhu Bio-B (02575.HK) has received Fast Track designation from the FDA for its product NG-350A, aimed at treating locally advanced rectal cancer with proficient mismatch repair (pMMR) [1] Group 1 - The product NG-350A is licensed from the clinical-stage oncology company Akamis [1] - The company holds exclusive rights for the development, production, and commercialization of NG-350A in the Greater China region [1]